Artificial Intelligence and Big Data in Pharma
March 21 2018, Max Planck Institute of Biochemistry, Munich
Overview about AI in Healthcare
Justus Wolff and Andreas Keck, Syte
Artificial Intelligence (AI) and Big Data are key drivers for disruption in many industries and change the way business works from its core. Major industries across different segments are increasingly investing in digital capabilities and not only after IBM Watson, the global players in healthcare are looking for strategies in this segment.
This presentation covers an introduction into AI strategy in healthcare as one of the largest application fields of AI. The content focuses on key definitions, concrete application cases and AI tailored enterprise valuation. The presentation is based on global practical experience in AI strategy and M&A in Digital Health at Syte and coauthored publications. Among others abstracts of two publications will be presented, namely “Too big to ignore – How to define enterprise value of AI and Big Data firms” and “Artificial Intelligence: Strategic Challenges for Established Companies” which are currently in press in the US and in Germany.
Justus is Manager for Strategy and M&A at Syte – Strategy Advisory for Digital Health.
Syte (ehealth-syte.com) is a global strategy and M&A advisory and has advised listed multinationals as for example Allianz, MetLife and Cochlear as well as cutting edge SMEs. Projects include for example digital business models for pharma, insurance and healthtech companies and M&A advisory projects for investments in data driven companies.
He is coauthor of several publications like “Too big to ignore – How to define enterprise value of AI and Big Data firms” and “Artificial Intelligence: Strategic Challenges for Established Companies”. Justus was lecturing on the topic “From Venture Capital to Venture Client” at IMD (International Institute for Management Development) in Switzerland and AI Strategy at the University of Luxembourg and the University of Passau. He holds a BSc in finance and a MSc in strategy and conducted his executive education at Said Business School, University of Oxford.
Dr. med Andreas Keck worked over 10 years as internist and interventional cardiologist at one of the largest cardiology departments in Europe. As senior doctor, he led international research teams for the development, study design/conduction and implementation of innovative technologies. He was co-founder of international medical start-ups and has more than 12 years of experience in strategy projects at the Boston Consulting Group and in an independent consulting company.
AI in personalized medicine
Pedro B. Faustino, SimplicityBio
From yesterday’s modern medicine to today’s personalized medicine and beyond; what is Artificial Intelligence, how is it being applied in medicine and what role do we want it to have? In this talk, Pedro Faustino will share his views on the subject, and hopes to challenge the audience to develop an opinion of how we can all shape its impact.
Pedro B. Faustino
Pedro B. Faustino is the COO and co-founder of SimplicityBio Ltd., a Swiss company developing a machine learning platform helping solve the question of “Which therapy, when and for which patient?”. He graduated with a MSc. in Electrical Engineering from TU Delft, Netherlands and an EMBA from EPFL, Switzerland.
AI in drug discovery
Jérémy Bernard, Exscientia
The centaur approach in drug discovery will be introduced to show how AI and drug hunters can work together to make better decisions. Results from current collaborations will illustrate how Exscientia is applying this approach to deliver an efficient drug discovery process and clinical candidates.
Jérémy is a co-inventor of the original Exscientia technology for the Automated Design of ligands to Polypharmacological Profiles, which was developed during his PhD in Dundee university with Pr. Andrew Hopkins in 2012. Jérémy graduated with a French “Diplôme d’Ingénieur Chimiste” from The Ecole Nationale Supérieure de Chimie de Montpellier and gained a MSc in Chemical Biology from the University of Montpellier II in 2008.
AI in preclinical and clinical stages
Gunjan Bhardwaj, Innoplexus
A complex systems view of life science mandates that we look at the data universe as a whole. Applying different AI approaches for use cases with razor sharp focus on tangible value can drive scale and scope advantages once the data challenge is addressed.
Gunjan is the Founder and CEO of the Innoplexus group. He was earlier with the Boston Consulting Group and before that the leader of the global business performance think-tank of Ernst & Young and a manager in the German practice with a solution focus on strategy and innovation. He has led projects in strategy, analytics and technology for various clients in different parts of the world. Gunjan was also a partner, senior-editor and advisor for a prominent online innovation management journal and was a member of the scientific advisory board of a US based not for profit institute researching in complexity sciences in the healthcare industry. Gunjan is also a guest lecturer at the European Business School for growth management based out of Frankfurt, Germany and FIA Business School in Sao Paulo. He has also been in the advisory board of a Future management initiative of a big Pharma company in Germany. He was also an honorary representative of the state of Baden-Württemberg to India. Gunjan has been publishing in many scientific and business journals such as the Harvard Business Review, MIT Sloan Review and Journal of Service Research. He has also published a book on marketing in emerging markets. He has studied at IIT Bombay, Pforzheim Business School, MIT Sloan and European Business School.